Immunology for
a Better Future
Learn More
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Advancing Therapeutic
Solutions
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
Focused on Improving
Lives
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Key Highlights
- AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
- Mar 27, 2025
- AIM ImmunoTech Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
- Mar 11, 2025
- AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
- Feb 28, 2025